Literature DB >> 32500764

Point-by-Point Progress: Gonorrhea Point of Care Tests.

Charlotte A Gaydos1, Johan H Melendez1.   

Abstract

INTRODUCTION: Point-of-care (POC) tests for Neisseria gonorrhoeae (Ng) are urgently needed to control the gonorrhea epidemic, so patients can receive immediate diagnoses and treatment. While the advent of nucleic acid amplification tests (NAATs) has improved the accuracy of Ng identification, very few POC assays are able to provide results of such tests at the clinical visit. Additionally, antimicrobial resistance (AMR) presents a unique treatment challenge for Ng. AREAS COVERED: This review notes that older POC tests have lower sensitivity for Ng, compared to the currently-available NAATs, and are not adequate for the current demand for high sensitivity. Promising newer assays, which can be used at the POC are covered. This review also includes data about clinicians' and patients' acceptability and expectations of POC tests for Ng, testing of extragenital specimens, pooling studies, as well as their impact clinically, and use in low-resource settings. EXPERT OPINION: The ability to use POC tests to identify and immediately treat Ng infections at the patient encounter offers many benefits and opportunities. POC tests for Ng are currently available, but not widely used especially in low-resource settings. Further development of POC tests with AMR testing capacity is needed to help guide antimicrobial stewardship.

Entities:  

Keywords:  Neisseria gonorrhoeae ; antimicrobial resistance; diagnostics; point-of-care tests; sexually transmitted infections

Year:  2020        PMID: 32500764      PMCID: PMC7483383          DOI: 10.1080/14737159.2020.1778467

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  84 in total

1.  Evaluation of the ResistancePlus GC (beta) assay: a commercial diagnostic test for the direct detection of ciprofloxacin susceptibility or resistance in Neisseria gonorrhoeae.

Authors:  Samantha Ebeyan; Madeline Windsor; Amanda Bordin; Lebogang Mhango; Simon Erskine; Ella Trembizki; Elisa Mokany; Lit Yeen Tan; David Whiley
Journal:  J Antimicrob Chemother       Date:  2019-07-01       Impact factor: 5.790

2.  Comparison of the Cepheid GeneXpert CT/NG assay to the Hologic Aptima Combo2 assay for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in self-collected rectal swabs.

Authors:  Laura Dize; Barbara Silver; Charlotte Gaydos
Journal:  Diagn Microbiol Infect Dis       Date:  2017-10-26       Impact factor: 2.803

3.  Ciprofloxacin May be Efficacious in Treating Wild-Type Gyrase A Genotype Neisseria gonorrhoeae Infections.

Authors:  Lao-Tzu Allan-Blitz; Peera Hemarajata; Romney M Humphries; Mabel Kimble; Sam Elias; Jeffrey D Klausner
Journal:  Sex Transm Dis       Date:  2018-04       Impact factor: 2.830

4.  Impact of specimen storage temperature and time on the implementation of GeneXpert® testing for sexually transmitted infections in resource-constraint settings.

Authors:  Liteboho D Maduna; Marleen M Kock; Andrew Medina-Marino; Jeffrey D Klausner; Remco P H Peters
Journal:  J Microbiol Methods       Date:  2019-09-10       Impact factor: 2.363

Review 5.  Gonorrhoea.

Authors:  Magnus Unemo; H Steven Seifert; Edward W Hook; Sarah Hawkes; Francis Ndowa; Jo-Anne R Dillon
Journal:  Nat Rev Dis Primers       Date:  2019-11-21       Impact factor: 52.329

6.  The Potential Population-Level Impact of Different Gonorrhea Screening Strategies in Baltimore and San Francisco: An Exploratory Mathematical Modeling Analysis.

Authors:  Minttu M Rönn; Christian Testa; Ashleigh R Tuite; Harrell W Chesson; Thomas L Gift; Christina Schumacher; Sarah L Williford; Lin Zhu; Meghan Bellerose; Rebecca Earnest; Yelena Malyuta; Katherine K Hsu; Joshua A Salomon; Nicolas A Menzies
Journal:  Sex Transm Dis       Date:  2020-03       Impact factor: 3.868

7.  Can Ciprofloxacin be Used for Precision Treatment of Gonorrhea in Public STD Clinics? Assessment of Ciprofloxacin Susceptibility and an Opportunity for Point-of-Care Testing.

Authors:  Johan H Melendez; Yu-Hsiang Hsieh; Mathilda Barnes; Justin Hardick; Elizabeth A Gilliams; Charlotte A Gaydos
Journal:  Pathogens       Date:  2019-10-14

8.  Impact of Rapid Susceptibility Testing and Antibiotic Selection Strategy on the Emergence and Spread of Antibiotic Resistance in Gonorrhea.

Authors:  Ashleigh R Tuite; Thomas L Gift; Harrell W Chesson; Katherine Hsu; Joshua A Salomon; Yonatan H Grad
Journal:  J Infect Dis       Date:  2017-11-27       Impact factor: 5.226

9.  Trends in Neisseria gonorrhoeae Antimicrobial Resistance over a Ten-Year Surveillance Period, Johannesburg, South Africa, 2008⁻2017.

Authors:  Ranmini Kularatne; Venessa Maseko; Lindy Gumede; Tendesayi Kufa
Journal:  Antibiotics (Basel)       Date:  2018-07-12

10.  Potential for Point-of-Care Tests to Reduce Chlamydia-associated Burden in the United States: A Mathematical Modeling Analysis.

Authors:  Minttu M Rönn; Nicolas A Menzies; Thomas L Gift; Harrell W Chesson; Tom A Trikalinos; Meghan Bellerose; Yelena Malyuta; Andrés Berruti; Charlotte A Gaydos; Katherine K Hsu; Joshua A Salomon
Journal:  Clin Infect Dis       Date:  2020-04-15       Impact factor: 9.079

View more
  7 in total

1.  A portable magnetofluidic platform for detecting sexually transmitted infections and antimicrobial susceptibility.

Authors:  Alexander Y Trick; Johan H Melendez; Fan-En Chen; Liben Chen; Annet Onzia; Aidah Zawedde; Edith Nakku-Joloba; Peter Kyambadde; Emmanuel Mande; Joshua Matovu; Maxine Atuheirwe; Richard Kwizera; Elizabeth A Gilliams; Yu-Hsiang Hsieh; Charlotte A Gaydos; Yukari C Manabe; Matthew M Hamill; Tza-Huei Wang
Journal:  Sci Transl Med       Date:  2021-05-12       Impact factor: 17.956

Review 2.  Bridging the gap between development of point-of-care nucleic acid testing and patient care for sexually transmitted infections.

Authors:  Kuangwen Hsieh; Johan H Melendez; Charlotte A Gaydos; Tza-Huei Wang
Journal:  Lab Chip       Date:  2022-02-01       Impact factor: 7.517

3.  Antimicrobial susceptibility testing of Neisseria gonorrhoeae using a phenotypic-molecular assay and lyophilized antimicrobials.

Authors:  Johan H Melendez; Fan-En Chen; Tza-Huei Wang
Journal:  Diagn Microbiol Infect Dis       Date:  2021-10-29       Impact factor: 2.983

4.  High-Resolution Melting Analysis to Detect Antimicrobial Resistance Determinants in South African Neisseria gonorrhoeae Clinical Isolates and Specimens.

Authors:  Nireshni Mitchev; Ravesh Singh; Veron Ramsuran; Arshad Ismail; Mushal Allam; Stanford Kwenda; Florah Mnyameni; Nigel Garrett; Khine Swe Swe-Han; Abraham J Niehaus; Koleka P Mlisana
Journal:  Int J Microbiol       Date:  2022-01-18

Review 5.  A Narrative Review of Where We Are With Point-of-Care Sexually Transmitted Infection Testing in the United States.

Authors:  Charlotte A Gaydos; Yukari C Manabe; Johan H Melendez
Journal:  Sex Transm Dis       Date:  2021-08-01       Impact factor: 2.830

6.  Visible colorimetric growth indicators of Neisseria gonorrhoeae for low-cost diagnostic applications.

Authors:  Taylor Mae Oeschger; David Carl Erickson
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

7.  Neisseria gonorrhoeae Multivalent Maxibody with a Broad Spectrum of Strain Specificity and Sensitivity for Gonorrhea Diagnosis.

Authors:  Jieun Jeong; Jae-Seok Kim; Junghyeon Lee; Yu Ri Seo; Eugene C Yi; Kristine M Kim
Journal:  Biomolecules       Date:  2021-03-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.